Open Access Full Text Article

CASE REPORT Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic[®] Software

Abel Saldarreaga Marin D Marc Cendros² Carlos | Ciudad 103 Ana Sabater 102

¹Bahía de Cádiz-La Janda Health District, Mobile Emergency Unit of the Andalusian Health Care, Service of Cádiz, Cádiz, Spain; ²Eugenomic, Barcelona, Spain; ³Biochemistry and Molecular Biology Unit, School of Pharmacy, University of Barcelona, Barcelona, Spain

Correspondence: Ana Sabater Eugenomic, c/ Londres 6, Barcelona, 08029, Spain Tel +34-93-292-2963 Email asabater@eugenomic.com

Abstract: This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes. The use of a drug interaction and personalized prescription software (g-Nomic[®]) revealed potential interactions, involving acetylsalicylic acid and several non-pharmaceutical products including ginger, blueberry extracts, pineapple juice, docosahexaenoic acid and liquorice. Correction of these interactions resulted in complete remission of the reported side effects. This supports the idea that non-pharmaceuticals potentiated the effects of acetylsalicylic acid on haemostasis, producing the bleeding that would have caused fatigue. It is important to use appropriate tools to detect drug interactions that also take into account commonly used nonpharmaceutical products. Drug interactions can be considered illnesses by themselves.

Keywords: pharmacogenetics. SNP. drug-drug interaction. druglifestyle interactions, drug-herb, software, bleeding, fatigue, polymedication, medication risk, pharmacogenetics software, personalized prescription

Introduction

Drug treatment can be affected by significant variability in the degree of response and the occurrence of side effects. Adverse drug reactions are responsible for considerable morbidity and mortality. Sometimes these undesirable effects are intrinsic to the drug, but in many cases they are due to drug-drug interactions.^{1,2} It is known that drug-drug interactions can trigger adverse effects of medicines that would have been safe if they had not been used in combination. In addition, other substances that are not usually considered pharmaceuticals, like herbal products, may also cause drug-lifestyle interactions. Recognising and managing these interactions can be an invaluable process in achieving safer therapy.

We present a case of a polymedicated patient who was taking apparently harmless substances and dietary supplements and who presented with bleeding and fatigue. This situation was resolved by identifying and managing drug interactions using g-Nomic[®] personalised prescription software.

Case Presentation

A 65-year-old Caucasian man with hypertension, type 2 diabetes, elevated LDLcholesterol and ischemic cardiomyopathy, wearing a stent, presented unexplained fatigue with physical activity and coagulation defects consisting of gingival bleeding and frequent bruising.

© 2021 Saldarreaga Marin et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission for nomercial lemited. The provided the work is properly attributed. For permission for commercial uses of this work, area see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Analytical Explorations

All biochemical parameters were within the normality except for elevated LDL-c levels. Hepatic and renal functions were normal (Alanine transaminase -ALT 17 U/L, aspartate transaminase AST 21 u/L, gamma-glutamyltransferase 24 U/L, creatinine 0.94 mg/dL, blood urea 35 mg/dL, glucose 95 mg/dL, glycosylated haemoglobin 6.1%). Prothrombin time (seconds): 10.2" (8.9–13.3). Normalized prothrombin time (INR): 0.90 (0.80–1.20).

At the moment of the consultation, the patient had the following treatment:

Telmisartan 40mg/d, metformin 850 mg/d, empagliflozin 40mg/d, bisoprolol 2.5/d, atorvastatin 40mg/d, clopidogrel 75mg/d and acetylsalicylic acid (ASA) 100mg/d.

Examination

Except for fatigue and bleeding, the patient showed good general condition; he was conscious, oriented and collaborative, eupnoeic at rest and afebrile. Cardiopulmonary auscultation and abdominal examination did not result in pathological findings. Basal oxygen saturation: 98%. Blood pressure: 138 mm Hg (systolic)/76 mm Hg (diastolic). Heart rate; 85 bpm. Respiratory rate at rest: 14 bpm. Temperature: 35.8 °C.

The patient's medication regime was evaluated using g-Nomic® software³ to check for interactions and possible genetic effects. In Figure 1 it is shown all the initial drugs entered in the personalized prescription software.

In addition, the same personalized prescription software was used to check for possible substances that could contribute to interactions even if they are not considered drugs per se, referred to in the software as lifestyle habits. After interviewing the patient about them, it was identified that the patient consumed 3 grams of docosahexaenoic acid (DHA) /day, blueberry and ginger extract supplements, and daily consumption of pineapple juice. In addition, the patient quit smoking nine years ago, and since then has been consuming liquorice ever since to support abstinence. Figure 2 shows the list of lifestyle

Active ingredients / Brand	name drug list				1 - 7 of 7 🧑
Add Active Ingredient (AI)					
Name	Surname		Med.histo	ory Num/Ref. Pa	tient
Active ingredient 🔹	Brand name drug 🔹	Medication ** start	Medication * end	Stop tacking 🤹	Delete/ Stop taking
Acetylsalicilic acid		31.05.2021	N/A	0	Delete Stop taking
Atorvastatin		31.05.2021	N/A		Delete Stop taking
Bisoprolol		31.05.2021	N/A		Delete Stop taking
Clopidogrel		31.05.2021	N/A		Delete Stop taking
Empagliflozin		31.05.2021	N/A		Delete Stop taking
Metformin		31.05.2021	N/A		Delete Stop taking
Telmisartan		31.05.2021	N/A		Delete Stop taking

Figure I All initial drugs entered in the personalized prescription software.

LifeStyle		1 - 20 of 46 >
Name Surname	Med.history Num/Ref.	Abel Case
Active ingredient 🐄	Verify interaction *	
Alcohol (Etanol)	Verify interaction	
Aloe vera (Aloe barbadensis)	Verify interaction	
Alpha-Lipoic Acid (ALA)	Verify interaction	
Aluminum	Verify interaction	
Arginine (Arginine)	Verify interaction	
Astragalus	Verify interaction	
Berberine (Berberis sp.)	See PGX Report tab to see interaction	
Black pepper (Piper nigrum)	See PGX Report tab to see interaction	
Blond plantain (Plantago ovata)	Verify interaction	
Blueberry (Vaccinium corymbosum, V. myrtillus)	Verify interaction	
Cat's claw (Uncaria tomentosa)	Verify interaction	
Chamomile (Matricaria chamomilla)	See PGX Report tab to see interaction	
Cinnamon (Cinnamomum verum)	Verify interaction	
Danshen (Salvia miltiorrhiza)	Verify interaction	
Embli (Phyllanthus emblica)	Verify interaction	
Feverfew (Tanacetum parthenium)	Verify interaction	
Filipendula ulmaria	Verify interaction	
Ginger (Zingiber officinale)	Verify interaction	
Ginkgo biloba-leaf extracts	Verify interaction	
Grapefruit (Citrus paradisi)	Verify interaction	
Horse-chestnut (Aesculus hippocastanum)	Verify interaction	
Karela (Momordica charantia)	Verify interaction	
Licorice (Glycyrrhiza glabra)	Verify interaction	
Linum usitatissimum	Verify interaction	
Methylthioninium chloride	See PGX Report tab to see interaction	
Milk thistle (Silybum marianum)	See PGX Report tab to see interaction	
Noni (Morinda citrifolia)	Verify interaction	
Oats bran (Avena sativa)	Verify interaction	
Omega 3 fatty acids	Verify interaction	
Pectin	Verify interaction	
Pine bark	Verify interaction	
Pineapple -juice	See PGX Report tab to see interaction	
Potasium	Verify interaction	
Primrose oil (Oenothera spp.)	Verify interaction	
Quinine	See PGX Report tab to see interaction	
Red Clover (Trifolium pratense)	See PGX Report tab to see interaction	
Red raspberry (Rubus idaeu)	See PGX Report tab to see interaction	
Resveratrol	Verify interaction	
Saint John's Wort (Hypericum perforatum)	Verify interaction	
Schisandra (Schisandra chinensis)	See PGX Report tab to see interaction	
Sulfisoxazole	See PGX Report tab to see interaction	
Tamarind (Tamarindus indica)	Verify interaction	
Turmeric (Curcuma longa)	See PGX Report tab to see interaction	
Vitamin B3 (niacin)	Verify interaction	
Willow Bark	Verify interaction	
Xiaoke Pill	Verify interaction	

Figure 2 Shows the list of all lifestyle habits that could interact with patient's medication, reported by the personalized prescription software.

habits that may interact negatively with the patient's prescription entered into the personalized prescription software. The physician should ask the patient if he/she takes any of these substances on a regular basis in his/her daily life. If so, the doctor should click on the hyperlink to make this lifestyle habits part of the prescription as a whole.

Actions and Outcome

After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions. Figure 3 shows drug-drug interactions as well as drug- lifestyle interactions. Figure 4 shows the possible interactions due to inhibitions and inductions caused by patient's polymedication. It is known that substances with inhibitory capacity can also impair enzyme activity even in the absence of loss-of-function variants. Therefore, a person who would be classified as a normal metaboliser based on a genetic test alone would experience a phenoconversion to a poor metaboliser when exposed to a strong inhibitor. Similarly, enzyme inducers can increase enzyme activity beyond what a genetic test might indicate. This reasoning can be extended to drug-herb and druglifestyle interactions as potential modulators of drug metabolism and thus drug response.

The patient was advised to discontinue the consumption of ginger, blueberry extracts and pineapple juice. The dose of omega-3 fatty acids was reduced from 3g/day DHA to 1g/day. Liquorice was maintained, but the patient was told to minimize its use.

As the patient was already being treated with a betablocker to control blood pressure, telmisartan was temporarily discontinued to minimise the side effects of the combination of two antihypertensive drugs.

Figure 5 shows the primary genes to be considered when checking the specific medication for to this clinical case. After assessing all drug interactions, no genetic testing of the patient was considered necessary.

The patient was scheduled for a follow-up evaluation two months later.

At the next visit, there was a clear improvement in both his clinical condition and general wellbeing. The coagulation defects had disappeared with no further gingival bleeding or skin bruising.

Blood pressure was normal (BP: 134/68 mmHg) despite the discontinuation of telmisartan, and it was considered that reinstating the antihypertensive was not justified. Furthermore, glycaemia was also correct (HbA1c:

5.4%) and it was decided to discontinue metformin leaving only Empagliflozin to manage the patient's diabetes.

The patient's general condition and well-being had also increased enormously: he did not complain of fatigue and had started exercising outdoors and working out at the gym three times a week.

Discussion

Drug interactions seem to have been the cause of the patient's worsening condition, as the improvement was remarkable after addressing the detected potential risks of interactions.

The main concern in this patient was the excessive bleeding. Several factors could have contributed to altered haemostasis, including impaired renal function, which could also explain the increased blood pressure. ASA has an anticoagulant action and may also reduce renal function, contributing to both said problems, and its effects could have been potentiated by other substances. Ginger has hypoglycaemic action, but has also been reported to inhibit thromboxane synthesis, so it may potentially interact with acetylsalicylic acid to potentiate the effects of this drug.⁴ Berries from the Vaccinium genus contain small amounts of salicylates, and berry juice in large quantities (more than 1L/day) or berry extracts may increase the hypoprothrombinaemia effects of acetylsalicylic acid.⁵ While 1L a day is too large to be a likely cause of interaction, the patient was taking an extract supplement, which usually contains higher amounts of active compounds than those present on juice or the berry itself. Pineapple juice, which the patient consumed daily, contains bromelain, a substance that can inhibit cytochrome P450 2C9,⁶ which is the main metabolic pathway for acetvlsalicylic acid.⁷ Therefore, regular intake of pineapple juice could have been an additional factor leading to higher exposure to salicylates.

All of this would contribute to increase the effects of salicylates on both platelet aggregation and blood pressure.

Hypoprothrombinaemia may have also been increased by omega-3 fatty acids, as the patient was consuming large doses of DHA. 8

Furthermore, liquorice has been reported to reduce the effects of the antihypertensive medication by increasing liquid retention.⁹

In this case, none of these products would have been considered dangerous on their own, as they are consumed by a large amount of people without incident. They would have been overlooked unless the personalised prescribing software had reported them as potential risks of interaction

Interactions Drug/Drug	and Drug/Lifestyle				1 - 8 of 8 🧿
Name	Surnar	me		Med.history Num/Ref	. Patient
Active ingredient	Category interaction	Orug/Lifesty	le interaction	1 Drug/Drug interaction	n 🚯
Metformin Telmisartan	hypoglycaemia.	IS: Blood glucose f a concomitant t	concentrations reatment.	ct of hypoglycemic agents should be monitored moi 03/2018	
Empagliflozin Telmisartan	hypoglycaemia.	IS: Blood glucose f a concomitant t	concentrations reatment.	ct of hypoglycemic agents should be monitored moi 03/2018	
Acetylsalicilic acid Telmisartan	is gradual and therefore consequences. MANAGEMENT OPTION an NSAID, using nonace	e if the use of NS. \S : The risk of int etylated salycilate	AIDs in the shor eraction can be es instead of an	ecause they reduce the re t term it is unlikely to hav minimized by using aceta NSAID or using the NSAIE it is warranted to monitor	e clinically relevant minophen instead of at low doses and for
Ginger (Zingiber officinale) Metformin	additíve effect can leac MANAGEMENT OPTION more closely. Ref: Zadoyan G, Fuhr U. Phe	I to hypoglycemia IS: In the concom enotyping studies	a. itant use, it is n to assess the e	nd/or lower blood glucose ecommended to monitor l ffects of phytopharmaceu ta Med. 2012 Sep;78(13):1	blood glucose levels
Bisoprolol Licorice (Glycyrrhiza glabra)	licorice, even in infusio Ref: Stockley, Ivan H. S	IS: It is recomment n doses. tockley's Herbal plements and nut	nded to avoid th Medicines Intera	of antihypertensives. le concomitant use of ant actions. A guide to the int conventional medicines.	eractions of herbal
Acetylsalicilic acid Clopidogrel Ginger (Zingiber officinale)	which it can interact w MANAGEMENT OPTION more closely. Ref:	ith anticoagulant IS: It is recomment of potential harm	s in a significan nded to avoid th nful interactions	e association and, if nece between anticoagulant/a	essary, monitor the INR
Acetylsalicilic acid Clopidogrel Omega 3 fatty acids	potentation in the action MANAGEMENT OPTION Cohen MG, Rossi JS, Ga	on of antiplatelet \S: Watch for sign rbarino J et al. Ins	agents. is of excessive p sights into the in	telet drugs result, by a sin olatelet antiaggregation. nhibition of platelet activa grel. Thromb Res. 2011 Oc	ation by omega-3
Acetylsalicilic acid Blueberry (Vaccinium corymbosum, V. myrtillus)	consumption of cranbe	erry juice is rather erry juice ingesti	on and clinical d	lrug-drug interaction pote	

Figure 3 Drug interactions and drug – lifestyle reported by the personalized prescription software.

My Patients	Patient data	Drugs Lif	feStyle (41)	Interactions (8) Genes PGX Report (5) Risks (4)			
Pharmacogenetic Report 1-3 of 3 0							
Show Secondary A Genes/Drugs interactions () Inhibitions and inductions () Specific remarks							
Name Surname Med.history Num/Ref. Patient							
Active ingredient	Brand name drug	Evidence icon	Gene	Relevant information			
Pineapple - juice			CYP2C9	Pineapple -juice is a potent inhibitor of the CYP2C9 enzyme, so the bioavailability of Acetylsalicilic acid may be increased by a factor greater than 5. It is recommended to replace Pineapple -juice, with another of similar effect that is not a potent enzyme inhibitor CYP2C9 to avoid toxicity due to overdose, except when there are guidelines that define the dose reduction for this drug.			
Licorice (Glycyrrhiza glabra)			АВСВ1 СҮРЗА4	 Being Licorice (Clycyrrhiza glabra), weak inducer of the efflux transport protein Pgp-MDR1, encoded by the gene ABCB1, a slightly lower plasma levels of expected will be achieved of the drugs Atorvastatin, so it would recommended to increase the dose by 20-30%. It is difficult to generalize and must see if there is specific information for each drug on drug monographs. Because Licorice (Clycyrrhiza glabra) is a weak inducer of the CYP3A4 gene/s, it can accelerate the metabolism of drugs that are substrates of i i.e. Clopidogrel*. Being a prodrug/s, its transformation to the active form can be accelerated. Usually this has no negative effects. However, if the pathway that is induced is purely for elimination and does not contribute the formation of active metabolites, the result would instead be a reduce efficacy. In some cases accelerated bioactivation can lead to overdose peaks. It is recommended to check the specific messages for more complete information. Since Licorice (Clycyrrhiza glabra) is/are weak inducer/s of the gene CYP3 it may accelerate the metabolism of drugs that are substrates of it: Atorvastatin, Bisoprolol. Therefore it will require higher doses to achieve the same therapeutic effect. It is recommended to increase the dose by 2 30%. 			
Acetylsalicilic acid			CYP2C19	Because Acetylsalicilic acid is a weak inducer of the CYP2C19 gene/s, it can accelerate the metabolism of drugs that are substrates of it, i.e. Clopidogrel*. Being a prodrug/s, its transformation to the active form can be accelerated. Usually this has no negative effects. However, if the pathway that is induced is purely for elimination and does not contribute to the formation of active metabolites, the result would instead be a reduced efficacy. In some cases accelerated bioactivation can lead to overdose peaks. It is recommended to check the specific messages for more complete information.			
Show Seconda	ry 🛕 Genes	/Drugs inte	eractions 🕕 I	nhibitions and inductions 📀 Specific remarks			

Figure 4 Pharmacogenetics interactions described by the personalized prescription software.

with the patients' medication. The proactive warning prompted the physician to ask the patient about the consumption of these products. Herbal products or extracts used as supplements, such as blueberry extracts, would perhaps have been considered at some point, while consumption habits, such as pineapple juice, would have remained unnoticed.

No specific cause of the fatigue was identified with certainty, but it was likely to be a side effect of the blood loss.

My Patients Patient data Drugs LifeStyle (43) Interactions (5) Genes PGX Report (5) Risks (4) Enter results of the genetic study. Request study if you did not do it. *********Included 95 genes for simulation*******							
Add Other Genes Results Name Surname Med.history Num/Ref.							
Active ingredient	Brand name drug	Evidence icon	Recommended genes according to active ingredients	†∔	Add genotype/ phenotype results		
Acetylsalicilic acid		3	CYP2C9		Add Results		
Atorvastatin		3 2 2	BCRP CYP3A4 SLCO1B1		Add Results Add Results Add Results		
Bisoprolol		4	СҮРЗА4		Add Results		
Clopidogrel		1	СҮР2С19		Add Results		
Empagliflozin		4	SLCO1B1 UGT1A9 UGT2B7		Add Results Add Results Add Results		
Add Other Genes Results							

Figure 5 Pharmacogenetics markers described by the personalized prescription software.

In this case, the extracts the patient used, containing blueberry and ginger, could have contributed to bleeding, in addition to DHA and pineapple juice. These substances in combination were considered a likely trigger for the gingival bleeding.⁹ It is not possible to know the relative contribution of these substances to the interaction, nor if a clinically meaningful interaction would still have happened without the presence of the whole polymedication. Caution is recommended whenever natural products are used in combination with drugs affecting haemostasis.

The patient's condition improved as the drug regimen was reduced and simplified, meaning that some drugs may

have been unnecessary in the first place. For example, the hypertension could have been secondary to the use of liquorice and salicylate potentiation, and in this case, discontinuation of these substances would have been more helpful in controlling blood pressure than starting telmisartan.

Conclusion

This case report serves to illustrate two concepts: I) the importance of recognizing the interactions of existing compounds in commonly consumed products, in this particular case with anticoagulants. It is therefore advisable to use drug interaction software that take into account lifestyle habits. II)

Be aware of the increased risk of drug-drug interactions in patients consuming multiple natural products not considered drugs, which may be the cause of many drug-drug interactions. While being aware of the dangers of polymedication with multiple therapeutic drugs, other substances such as herbal products and dietary supplements, should not be disregarded. Reducing the drug regimen may occasionally lower the amount and severity of drug interactions, provided that the remaining drugs are enough to control the pathology. This work emphasizes the need for personalized approaches for patient empowerment in both clinical settings and home health care.

Consent Form

Consent was obtained from the patient to allow publication of his medical record. The patient was informed that his case of polymedication would be presented as a case report to the scientific community in order to let other healthcare professionals know what his treatment was like and how it has evolved.

The patient signed a consent form to authorise his doctor to record his medical history for the purpose of a scientific publication on his health conditions. He agreed to have his medical records recorded for the named purpose of a scientific publication. No ethics statement from the institution was required, the sole statement from doctor was needed.

Disclosure

Marc Cendrós and Ana Sabater work for EUGENOMIC S. L. and are directly involved in the development of the g-Nomic[®] the personalized prescription software, but neither they nor anyone at Eugenomic has had any role

Pharmacogenomics and Personalized Medicine Publish your work in this journal

Pharmacogenomics and Personalized Medicine is an international,

peer-reviewed, open access journal characterizing the influence of

genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for

improved safety, efficacy and sustainability. This journal is indexed

Submit your manuscript here: https://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal

970 🛐 😏 in 🔼 DovePress

in the management and clinical evaluation of this case beyond assisting the medical professionals in using the software. In addition, Mrs Ana Sabater has a patent g-Nomic issued to Eugenomic. The authors declare no other conflicts of interest in this work.

References

- Nikolic B, Jankovic S, Stojanov O, Popovic J. Prevalence and predictors of potential drug-drug interactions. *Cent Eur J Med.* 2014. doi:10.2478/s11536-013-0272-4
- McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. *Am J Med.* 2006;119(8):624–638. doi:10.1016/j. amjmed.2005.10.039
- Sabater A, Ciudad CJ, Cendros M, Dobrokhotov D, Sabater-Tobella J. G-nomic: a new pharmacogenetics interpretation software. *Pharmgenomics Pers Med.* 2019. doi:10.2147/PGPM.S203585
- Tsai HH, Lin HW, Lu YH, Chen YL, Mahady GB. A review of potential harmful interactions between anticoagulant/antiplatelet agents and chinese herbal medicines. *PLoS One.* 2013. doi:10.1371/ journal.pone.0064255
- Srinivas NR. Cranberry juice ingestion and clinical drug-drug interaction potentials; review of case studies and perspectives. *J Pharm Pharm Sci.* 2013;16(2):289. doi:10.18433/j3ng6z
- Hidaka M, Nagata M, Kawano Y, et al. Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro. *Biosci Biotechnol Biochem*. 2008;72(2):406–411. doi:10.1271/bbb.70511
- Agundez J, Martinez C, Perez-Sala D, et al. Pharmacogenomics in Aspirin Intolerance. *Curr Drug Metab.* 2009;10(9):998–1008. doi:10.2174/138920009790711814
- Cohen MG, Rossi JS, Garbarino J, et al. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel. *Thromb Res.* 2011;128(4):335–340. doi:10.1016/j.thromres.2011.04.023
- Stockley's herbal medicines interactions: a guide to the interactions of herbel medicines, dietary supplements and nutraceuticals with conventional medicines. *Choice Rev.* 2010. Availble form: https://www.access data.fda.gov/drugsatfda_docs/label/2016/204353s020lbl.pdf. Accessed August 2, 2021. doi:10.5860/choice.47-2357

Dovepress

on the American Chemical Society's Chemical Abstracts Service (CAS). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.